
Biogen
BIIB · NASDAQ · Biotechnology
Quotes delayed up to 15 min. Updated 16 Nov, 16:00 New York time
- Market cap
- $37,5 bn
- Div. yield
- —
- Year to date
- +44,0%
Ratio score
based on 8 metrics as of 16.11.2026 ·
Verdict by our methodology based on current metrics. Not an investment recommendation.
Key metrics
1 ✓ · 3 — · 4 ✕ · 2 n/a · hover over a row or tap it to see the trend
All metrics
| Metric | Value | 5-year median | Industry median |
|---|---|---|---|
| P/E TTM | 107,8 | 18,5 | 42,1 |
| Forward P/E | 16,5 | — | 18,7 |
| PEG | 22,4 | — | 4,1 |
| P/S | 3,6 | 3,2 | 6,6 |
| EV/EBITDA | 36,2 | 13,0 | 28,2 |
| P/FCF | 22,1 | — | 26,0 |
| P/B | 2,0 | 2,1 | 9,8 |
Industry median — across 6 profitable companies in “Biotechnology” in Ratio. Revenue and EPS forecasts for future years and the number of employees are in the paid data plan.
Price chart
Compare with
Choose a stock
Closing prices adjusted for splits and dividends. The S&P 500 index and the intraday chart come later.
Analysts
Ratings, 44 analysts
- Buy
- 32
- Hold
- 11
- Sell
- 1
Beat the EPS forecast in 4 of the last 4 quarters
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| Q3 2026 | 2,03 | 2,62 | Up +28,9% |
| Q2 2026 | 3,01 | 3,60 | Up +19,8% |
| Q1 2026 | 2,83 | 3,57 | Up +26,3% |
| Q4 2025 | 1,65 | 1,99 | Up +20,9% |
Price targets and yearly revenue and EPS forecasts are in the paid data plan. These are analysts' opinions, not our verdict.
Financials in charts
| Metric | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2,80 bn | 2,74 bn | 2,48 bn | 2,28 bn | 2,53 bn | 2,65 bn | 2,43 bn | 2,45 bn | 2,47 bn | 2,46 bn | 2,29 bn | 2,39 bn |
| EPS | −0,14 | 0,66 | 2,15 | −0,35 | 3,17 | 4,33 | 1,64 | 1,83 | 2,66 | 4,00 | 2,70 | 1,71 |
| Margin | −0,7% | 3,6% | 12,9% | −2,1% | 18,4% | 24,0% | 9,9% | 10,9% | 15,8% | 23,7% | 17,2% | 10,5% |
| FCF | 600 m | 408 m | 594 m | 468 m | 1,23 bn | 134 m | 222 m | 722 m | 901 m | 592 m | 507 m | −52,7 m |
From SEC reports. TTM is the sum of 4 quarters; a year is TTM at the end of the calendar year. Forecast bars are in the paid data plan.
Owners
Ownership structure and major holders (13F filings) are in the paid data plan. They are not part of the score or the traffic light.
Insider trades over 12 months
Over 12 months: purchases $585 (1 person), sales $905 414.
| Name | Amount | Shares | Price |
|---|---|---|---|
| minor lloyd4 Aug 2026 · sale | $119 169 | 593 | $200,96 |
| minor lloyd3 Aug 2026 · sale | $120 581 | 593 | $203,34 |
| murphy nicole12 Feb 2026 · open-market purchase | $585 | 3 | $195,04 |
| singhal priya9 Feb 2026 · sale | $531 548 | 2 660 | $199,83 |
| singhal priya2 Feb 2026 · sale | $134 116 | 748 | $179,30 |
SEC Form 4. Titles and trading plans are not in the data. They are not part of the score or the traffic light.
About the company
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Country
- US
- IPO date
- 17 Sep 1991
- Website
- www.biogen.com
Company description, revenue by segment and region, and the CEO will come later.
Earnings
- Next report
- date not announced
An AI summary of the earnings call will come later.
Peers
| Company | Price | ||||
|---|---|---|---|---|---|
INCYIncyte | $120,27 | 44★★★★★★★would watch | 61,1 | +24,9% | 6,7% |
MRNAModerna | $215,27 | 22★★★★★★would not consider | — | +13,1% | −110,5% |
REGNRegeneron Pharmaceuticals | $952,40 | 67★★★★★★★★★would watch | 20,5 | +18,6% | 28,5% |
VRTXVertex Pharmaceuticals | $537,79 | 72★★★★★★★★★would consider | 33,7 | +10,5% | 30,7% |
GILDGilead Sciences | $167,58 | 25★★★★★★★would not consider | — | +6,5% | −12,5% |
Ratio — a score by our methodology, not an investment recommendation.




